Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Warsaw, Poland.
Phytochem Anal. 2020 Jan;31(1):57-67. doi: 10.1002/pca.2866. Epub 2019 Jul 8.
In European traditional medicine, common ash leaf infusion is recommended by European Medicines Agency to treat minor articular pain and to increase the amount of urine for flushing minor urinary complaints. However, a comprehensive ultra-high-performance liquid chromatography diode array detector electrospray ionisation tandem mass spectrometry (UHPLC-DAD-ESI-MS/MS) analysis of this pharmacopeial plant material has never been performed. Moreover, the number of biological and pharmacological investigations proving the usefulness of this plant material in recommended traditional uses is surprisingly small.
Phytochemical profiling of ash leaf samples from different commercial and natural sources and the determination of the in vitro effects on inflammatory mediators in a model of human neutrophils.
Ash leaf samples were characterised by total hydroxycinnamic acid content and by high-performance thin layer chromatography (HPTLC), UHPLC-DAD-ESI-MS/MS methods. The effects of leaf infusions on reactive oxygen species (ROS), tumor necrosis factor (TNF-α), interleukin 8 (IL-8), interleukin 1β (IL-1β), and monocyte chemoattractant protein 1 (MCP-1) production by neutrophils were measured using luminol-dependent chemiluminescence and enzyme-linked immunosorbent assay (ELISA).
In ash leaf samples 64 compounds were identified or partly identified together with four unknown compounds. The major compounds detected belong to different structural groups, including phenolic acid derivatives, phenylethanoids, flavonoids, iridoids, secoiridoids and lignans. The major compounds detected in ash samples were chlorogenic acid, quercetin-3-O-rutinoside, verbascoside, oleuropein and ligstroside. However, one sample contained coumarin derivatives. This finding suggested adulteration with other Fraxinus species and/or plant parts. All infusions were able to inhibit ROS, cytokine and chemokine production.
The performed phytochemical and biological analyses contribute to the knowledge about this pharmacopeial plant material and supports its traditional use to treat minor inflammatory complaints.
在欧洲传统医学中，欧洲药品管理局建议使用普通灰树叶浸剂来治疗轻微关节疼痛，并增加尿液量以冲洗轻微的尿路不适。然而，对这种药典植物材料从未进行过全面的超高效液相色谱二极管阵列检测电喷雾串联质谱（UHPLC-DAD-ESI-MS/MS）分析。此外，证明这种植物材料在推荐的传统用途中的有效性的生物和药理学研究数量少得惊人。
对来自不同商业和天然来源的灰树叶样品进行植物化学分析，并测定其对人中性粒细胞炎症介质的体外作用。
采用总羟基肉桂酸含量和高效薄层色谱（HPTLC）、UHPLC-DAD-ESI-MS/MS 方法对灰树叶样品进行表征。采用发光依赖性化学发光和酶联免疫吸附试验（ELISA）测定叶浸剂对中性粒细胞产生活性氧（ROS）、肿瘤坏死因子（TNF-α）、白细胞介素 8（IL-8）、白细胞介素 1β（IL-1β）和单核细胞趋化蛋白 1（MCP-1）的影响。
在灰树叶样品中，共鉴定或部分鉴定了 64 种化合物，此外还鉴定了 4 种未知化合物。检测到的主要化合物属于不同的结构群，包括酚酸衍生物、苯乙醇苷、类黄酮、环烯醚萜、裂环烯醚萜和木脂素。在灰树叶样品中检测到的主要化合物为绿原酸、槲皮素-3-O-鼠李糖苷、毛蕊花糖苷、橄榄苦苷和石竹苷。然而，有一种样品中含有香豆素衍生物。这一发现表明存在与其他 Fraxinus 种和/或植物部分的掺假。所有浸剂都能够抑制 ROS、细胞因子和趋化因子的产生。
进行的植物化学和生物学分析有助于了解这种药典植物材料，并支持其用于治疗轻微炎症的传统用途。
